Overview

Efficacy of Diacerein Supplementation on Interleukin-1, Hs-CRP, TNF- Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang

Status:
COMPLETED

Trial end date:
2024-11-08

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are: * Does diacerein lower levels of inflammatory markers like interleukin-1, hs-CRP, and TNF-? * Does diacerein improve blood sugar control? * What side effects or problems do participants have when taking diacerein? Researchers will compare diacerein to a placebo (a look-alike substance with no active drug) to see if it works better for managing type 2 diabetes. Participants will: * Be adults aged 40-60 with uncontrolled type 2 diabetes * Take either diacerein or a placebo every day for 12 weeks * Visit the clinic for blood tests and monitoring at the beginning and end of the trial * Be evaluated for side effects and medication adherence\]

Phase:

PHASE2

Details

Lead Sponsor:

Universitas Sriwijaya

Collaborator:

Indonesia Endowment Fund for Education (LPDP), Ministry of Finance Republik of Indonesia

Treatments:

diacerein